Introduction
Sleep-disordered breathing is characterized by instantaneous cessations in the rhythm of breathing (apneas) or momentary or prolonged reduction in the amplitude of breathing (hypopneas).
Central sleep apnea accounts for under 5% of patients presenting for sleep apnea evaluation. 5, 6 Obstructive and central sleep apnea can co-occur, but there are distinct risk factors for central apnea including heart failure, stroke, high altitude, and opioid medication use. 6 Data on environmental contributors to sleep apnea are few. Associations with air pollutants were identified in 2 recent populationbased studies 7, 8 ; an increased risk was reported in World Trade Center-exposed rescue or recovery workers. 9 Two smaller studies have reported associations with solvent exposure. 10, 11 Both organophosphate and carbamate pesticides act by inhibiting acetylcholinesterase, an enzyme that hydrolyzes acetylcholine. Therefore, these agents can interfere with neuronal function, including control of respiration. 4 In pesticide poisoning, respiratory depression occurs and may be fatal. 12, 13 In animal studies, exposure to these pesticides elicits a spectrum of neurochemical, neurophysiological, and neurobehavioral deficits including respiratory depression and interference with sleep-wake cycles. 14 Thus, exposure to pesticides that inhibit acetylcholinesterase is potentially relevant to sleep apnea in humans. Pesticides in other chemical classes are also neurotoxic and could theoretically be relevant to sleep apnea. 15 Recent data suggest that carbamates can interact with the melatonin receptor 16 and that melatonin may play a role in sleep apnea, [16] [17] [18] providing an alternative or complementary mechanism for carbamates to impact this disorder.
No epidemiological studies exist of sleep apnea in relation to pesticide exposure. We aimed to address this gap by investigating associations between sleep apnea and pesticide exposure among male pesticide applicators in the Agricultural Lung Health Study (ALHS).
Participants and methods

Study population
The ALHS is a case-control study of current asthma nested within the prospective Agricultural Health Study (AHS). The We included 3 categories of asthma cases: doctordiagnosed current asthma (n = 876), potential undiagnosed asthma based on current asthma symptoms and medication use in nonsmokers (n = 309), and overlapping diagnoses of current asthma and either chronic obstructive pulmonary disease or emphysema in nonsmokers (n = 38). Noncases were randomly selected from those without the above conditions. We analyzed only the 1596 male pesticide applicators; 97% of pesticide applicators were men.
Sleep apnea assessment
Information on physician-diagnosed sleep apnea came from the ALHS computer-assisted telephone interview. We classified participants who reported "yes" to "Have you ever been told by a doctor that you have sleep apnea?" and "yes" to 1 of 4 possible sleep apnea treatments ("CPAP," "surgery," "bi-level," or "other oral device") as sleep apnea cases (n = 236). Requiring treatment in the definition increases reliability of this self-reported outcome. 22 Participants reporting "yes" to physician-diagnosed sleep apnea but not reporting a treatment for sleep apnea were excluded from analysis (n = 49). Otherwise, individuals were classified as non-cases (n = 1360).
Assessment of pesticide exposure
On earlier AHS questionnaires (www.aghealth.nih.gov), individuals provided names of chemicals used ever in their lifetimes ( Phase 1, 1993 Phase 1, -1997 , in the most recent farming season ( Phase 2, 1999 Phase 2, -2003 , and since last study contact (Phase 3, 200-2010). Reported names were linked to pesticide active ingredient names using the Environmental Protection Agency (EPA) Pesticide Classification Code. 23 We analyzed the 63 pesticides reported by N1% of applicators at Phase 3 that were also reported by at least 5 (of 236) sleep apnea cases. The 63 pesticides included 40 herbicides and plant growth regulators, 19 insecticides, 3 fungicides, and 1 rodenticide. For 22 of the 63 pesticides, we had data on lifetime days of exposure, from the AHS Phase 1 enrollment questionnaire, to assess doseresponse to individual pesticides. 23 We divided lifetime days of use into approximate tertiles for comparison with never users.
Statistical analyses
Using logistic regression, we estimated odds ratios (ORs) and 95% confidence intervals (CIs) for both ever-never pesticide exposure and lifetime days of pesticide exposure in relation to sleep apnea. Consistent with previous AHS analyses, we included continuous age and state (North Carolina or Iowa) in all models. We additionally included asthma status, the design variable for selection of ALHS participants.
We evaluated as potential covariates additional variables implicated in sleep apnea etiology from the literature including body mass index (BMI, continuous), history of diabetes, cardiovascular disease, hypertension, alcohol use (24-hour recall), caffeine intake (24-hour recall), and smoking (never, past, current, and pack-years). We calculated BMI from height and weight measured at the ALHS home visit. Individuals were classified as having cardiovascular disease if they answered "yes" to either ever experienced heart failure (asked in ALHS) or ever experienced a stroke (asked at AHS Phase 3). Final models included all the aforementioned covariates except alcohol use, caffeine intake, or smoking because they did not separately change regression coefficients by at least 10%.
Analyses included the 1569 individuals (98.3% of 1596) with complete covariate data (234 cases of sleep apnea and 1335 non-cases). A secondary analysis evaluated waist circumference, measured at the ALHS home visit, as an alternative adiposity adjustment variable to BMI (sleep apnea cases = 227, non-cases = 1307).
In additional analyses, we compared the year of first pesticide exposure to onset of sleep apnea. We also examined effect modification, and interaction, separately by asthma status and personal protective equipment use. In addition to the uncorrected P values presented in the tables, we calculated false discovery rate-adjusted P values (P FDR ) for the primary analysis, accounting for 63 tests using the Benjamini-Hochberg method. 24 Adjustment variables were the same as in the main analyses. We used SAS (SAS Institute Inc, Cary, NC, Version 9.3, except for tetrachoric correlations calculated using Version 9.4). Analyses used the following releases of the AHS data: P3REL201209.00, PIREL201209.00, and AHSREL201304.00.
Results
Nearly all participants were white (98.4%); few (b5%) were current smokers. Sleep apnea cases were slightly older than noncases ( Table 1) . As expected, BMI was higher among cases (Table 1) ; the adjusted OR per unit increase in BMI was 1.16 (95% CI 1.13-1.19). Sleep apnea was more common among asthmatics (Table 1) : adjusted OR 2.47, 95% CI 1.87-3.27. The 234 sleep apnea cases reported the following use of each of the queried treatments: "CPAP" (n = 215, 91.9%), "surgery" (n = 16, 6.8%), "bi-level" (n = 23, 9.8%), and "other oral device" (n = 22, 9.4%); more than one treatment could be listed.
We evaluated ever/never use of 63 pesticides in relation to sleep apnea. The 63 pesticides included 40 herbicides and plant growth regulators, 19 insecticides, 3 fungicides, and 1 rodenticide. Four pesticides were associated with sleep apnea at nominal P b .05 (Table 2) . Carbofuran, a carbamate pesticide, was the most statistically significant finding (P = .0002) with the largest number (n = 100) of exposed cases (OR 1.83, 95% CI 1.34-2.51) ( Table 2 ). Among the 3 carbamate pesticides, only carbofuran gave P b .05, but ORs for both aldicarb (OR 1.52, 95% CI 0.80-2.88) and carbaryl (OR 1.11, 95% CI 0.81-1.54) ( Table 2) were also above 1. Bifenthrin, a pyrethroid, was also positively associated with sleep apnea at P b .05 but with wide CIs reflecting only 5 exposed cases (OR 4.39, 95% CI 1.33-14.46, P = .015). Two pesticides showed inverse associations at nominal P b .05: picloram, an acetic acid herbicide (25 exposed cases, OR 0.61, 95% CI 0.38-1.00, P = .048), and metalaxyl, a fungicide (34 exposed cases, OR 0.59, 95% CI 0.38-0.92, P = .020) ( Table 2 ). When we control the FDR among all 63 pesticides, only the association with carbofuran (P FDR = .01) meets the P FDR b .05 threshold. The P FDR values are very high for the associations with other 3 pesticides with uncorrected P b .05 (P FDR : .510 for picloram, .42 for both bifenthrin and metalaxyl).
Although we hypothesized that organophosphate insecticides might be related to sleep apnea because, like carbamates, they inhibit acetylcholinesterase, none among 8 were associated at nominal P b .05 (Table 2 ). Among the 3 with ORs N1.00 (disulfoton, tebupirimfos, and terbufos), terbufos was the most strongly associated with sleep apnea (124 exposed cases, OR 1.34, 95% CI 0.97-1.85, P = .072, P FDR = .51).
Participants were queried on prior AHS questionnaires about "unusually high personal exposure" incidents. There were 334 incidents reported by 298 participants. Deleting the 7 participants reporting a carbofuran incident (1 case and 6 non-cases) changed the OR only from 1.83 to 1.84 (95% CI 1.34-2.52).
For carbofuran, all 96 (of 100) sleep apnea cases with available timing data reported first exposure before onset of sleep apnea; use began a median of 26.5 years before (interquartile range = 19.5-32.5). We had data on lifetime days of use for carbofuran (Table 3) . The positive association with carbofuran did not attenuate at higher exposures (P trend = .003).
Smoking was not significantly associated with sleep apnea (crude OR 0.59, 95% CI 0.27-1.31) in our population with few current smokers, nor was current alcohol intake (crude OR 1.18, 95% CI 0.85-1.64). Therefore, neither was included in our primary models. However, adjustment did not materially alter results. The OR for carbofuran was 1.84 (95% CI 1.34-2.53) after smoking adjustment and remained 1.83 (95% CI 1.33-2.51) after alcohol adjustment.
We adjusted for BMI because of its established relationship with sleep apnea. Waist circumference, a more specific index of central obesity, was too highly correlated with BMI (Pearson correlation = 0.88) to include both in models. Results were very similar when waist circumference replaced BMI in models for any of the 4 pesticides associated with sleep apnea at P b .05; OR for carbofuran was 1.81 (95% CI 1.31-2.49) vs 1.83 with BMI adjustment.
We saw no consistent effect measure modification by use of personal protective equipment, defined by use of respirator or dust mask. Likewise, results did not differ materially by asthma status (data not shown).
Discussion
In a cohort of male pesticide applicators, primarily farmers, we examined 63 pesticides in relation to sleep apnea. The most statistically significant association was for the carbamate pesticide carbofuran (OR 1.83, 95% CI 1.34-2.51, P = .0002). We confirmed that exposure to carbofuran began before the reported age of onset of sleep apnea for all cases with information on timing of first exposure.
The primary mode of action of carbofuran, like other carbamates and organophosphates, is via inhibition of the enzyme acetylcholinesterase. Organophosphates are regarded as irreversible inhibitors of acetylcholinesterase, whereas carbamates, including carbofuran, are slowly reversible inhibitors. With either, acetylcholine accumulates at nerve junctions, leading to overstimulation of acetylcholine receptors with later toxicity and potential perturbation of the sympathetic, parasympathetic, and peripheral nervous systems. 4, 25 Acetylcholinesterase acts on cholinergic neurons involved in control of breathing in the sleep-wake cycle. 1 Poisoning by any pesticides with this mechanism of action could result in respiratory depression. 4, 26 Thus, carbamates could play a role in the onset and/ or progression of central sleep apnea. Carbofuran can influence neurologic function via mechanisms other than acetylcholinesterase inhibition. In fish, carbofuran impacts levels of other neurotransmitters including dopamine, norepinephrine, and serotonin. The degree and direction of these changes vary by brain region. 27 Behavioral changes observed in fish after carbofuran exposure may be more sensitive indicators of neurotoxicity than altered brain catecholamine levels. 28 Carbofuran increased various oxidative stress parameters in the rat brain and produced motor and cognitive deficits; administration of the antioxidant Nacetylcysteine reduced these effects. 29 Of note, recently, a computational approach has shown that carbofuran mimics melatonin, a critical hormone in the sleep-wake cycle, and can bind to its receptor. 16 The increasing data implicating melatonin, a hormone crucial in the regulation of the sleep-wake cycle, in the sleep apnea or its severity 17, 18, 30 together with the ability of carbofuran to mimic melatonin 16 provide an alternative or complementary mechanism for an impact of carbofuran exposure on sleep apnea. Because obstructive sleep apnea is much more common than central, most of the sleep apnea in our study likely has a strong obstructive component. The etiology of obstructive and central sleep apnea is often mixed, and a putative cause of central sleep apnea could be synergistic with causes of the obstructive disorder. The overlap between central sleep apnea and obstructive sleep apnea suggests that some common mechanisms are likely involved. Ideally, we would have classified sleep apnea based on objective measures such as polysomnography. Instead, we identified sleep apnea from self-report of doctor diagnosis plus treatment. Requiring treatment in the definition increases reliability of this self-reported outcome. 22 Because bias in estimating relative measures of association increases with a case definition that is less specific but more sensitive, 31 requiring treatment in the definition increases specificity of the outcome reducing potential bias. Sleep apnea prevalence as defined in our study of older men (mean age 63.4 years) was relatively high at 14.8%; reported prevalence of obstructive sleep apnea in US men aged 45-64 is 4.7%. 5 Our higher prevalence of sleep apnea reflects, in part, oversampling of asthmatics; increased rates of sleep apnea reported in asthmatics were confirmed in our analysis. 32 We also had a relatively high prevalence of sleep apnea reported by non-cases (10.8%). However, based on polysomnography, much sleep apnea in the general population is undiagnosed, making the true prevalence uncertain. 22 Because we used self-reported sleep apnea rather than polysomnography, our noncase group likely includes some individuals with undiagnosed sleep apnea; this misclassification will tend to attenuate associations with pesticide exposure rather than result in a spurious positive association. Alternatively, if likelihood of diagnosis with and treatment for sleep apnea is related to pesticide use, bias away from the null could result. Sleep apnea risk factors such as higher BMI and cardiovascular disease increase likelihood of referral for evaluation and thus physician diagnosis. 22, 33 If these factors are related to prior pesticide use, confounding could occur; however, we adjusted for both. The use of self-reported pesticide exposure creates the possibility of exposure misclassification. Nonetheless, data from the parent AHS support the validity of self-reporting in our study population. Few AHS pesticide applicators self-reported a decade of first use inconsistent with the year a pesticide was first registered for use in the United States. 34 Overestimation of use duration was very low for carbofuran (b1%), our primary finding. 34 Among orchardists, repeatability of reports of ever use approximately 20 years after initial report was found to be sufficiently accurate for epidemiological analyses, especially for more commonly used pesticides. 35 Our study has other limitations. With 234 cases, few were exposed to some individual pesticides. Lifetime days of use information, available for some pesticides, was likely underestimated because it was collected on the first AHS questionnaire. However, that questionnaire was completed prior to the reported year of sleep apnea onset for nearly all cases (92%) providing prospective data for this analysis. Because the response rate for entry into the ALHS was about 50%, selection bias is possible if nonresponse was jointly related to sleep apnea diagnosis and pesticide use. Earlier questionnaires did not query sleep apnea, so we cannot estimate the response rate with respect to this outcome. However, sleep apnea is more common in asthmatics, and the response rate was very similar by asthma status. 20 Using asthma as a surrogate outcome to assess selection bias, it is reassuring that the association between asthma and carbofuran is very similar among all 23,498 male applicator respondents to the AHS Phase 3 questionnaire from whom ALHS participants were sampled (OR 1.09, 95% CI 0.97-1.23) and in ALHS participants (OR 1.18, 95% CI 0.95-1.47). Lifetime days of use of carbofuran varied relatively little, and ORs for sleep apnea were elevated at the lowest tertile of exposure (b14.5 lifetime days). Even if we underestimated lifetime exposure, we do not know if exposure at this level is sufficient to induce chronic effects on control of breathing in sleep apnea.
Our study has several strengths. We could assess temporality of sleep apnea onset in relation to first exposure to specific pesticides. For carbofuran, first use preceded diagnosis for all cases with temporal information. Use of specific pesticides was much higher in our farming population than in the general population, thereby increasing power. We had some data to evaluate dose-response with cumulative lifetime days of pesticide exposure and data on pesticide poisoning events. We also could adjust for various potential confounders including BMI and waist circumference based on objective measurements.
In 2009, the US EPA canceled the use of carbofuran on crops for human or animal consumption based on evidence of toxicity. 36 Canada and the European Union have also canceled its use, but it is still used in some other countries. US EPA classifies carbofuran as a Toxicity Category One pesticide, the most toxic category. Because of the steep exposure-response curve, small differences in exposure may lead to adverse effects, and concern has been raised, especially for children, because of residual carbofuran in the food supply. 36 We found little evidence of association between sleep apnea and organophosphates; however, since the 1990s, when our cohort was enrolled, carbamates have been the most commonly used pesticides, largely replacing organophosphates. Before cancellation, carbofuran was the most commonly used carbamate in US agriculture.
Our motivating hypothesis was based on acetylcholinesterase inhibition by organophosphates and carbamates. However, because other mechanisms may be involved in neurotoxicity of these pesticide classes and others, we examined all 63 individual pesticides. 15, 29, 37 We note that about 3 of 63 tests would be expected to result in P b .05 by chance alone, and we identified 4, including the carbamate carbofuran (P = .0002). We saw modest correlation of ever use among the 63 pesticides: 18% of all tetrachoric correlations were N0.4; Bonferroni correction for multiple testing would be conservative, especially with positively correlated tests, increasing the chance of false negatives. Carbofuran would pass a Bonferroniadjusted critical P value of .05/63 = .0008. However, similar conclusions are obtained when we control the FDR across all 63 pesticides using the Benjamini-Hochberg procedure, which is less conservative than a Bonferroni correction; only the association with carbofuran (P FDR = .01) meets a .05 P FDR threshold, whereas the other 3 pesticides with uncorrected P b .05 for association with sleep apnea have high P FDR values (.42-.51).
Conclusions
We conducted the first epidemiological study investigating the association of pesticide exposure and sleep apnea. Our results in a US male farming population suggest that exposure to carbofuran is positively associated with sleep apnea.
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